10-Q: Akebia Therapeutics Reports Q3 2024 Results, Navigates Vafseo Launch and Auryxia Exclusivity Loss

Akebia Therapeutics reports a net loss of $20 million for Q3 2024, with product revenue declining, while preparing for the launch of Vafseo and facing Auryxia's loss of exclusivity.

Summary

• Akebia Therapeutics reported a net loss of $20 million for the third quarter of 2024, compared to a net loss of $14.5 million in the same period of 2023.
• Product revenue decreased to $35.6 million in Q3 2024 from $40.1 million in Q3 2023, primarily due to lower sales volume of Auryxia.
• License, collaboration, and other revenue also saw a slight decrease, falling to $1.8 million from $1.9 million year-over-year.
• The company's operating expenses decreased slightly to $35.8 million in Q3 2024 from $37.1 million in Q3 2023.
• Research and development expenses decreased to $8.5 million in Q3 2024 from $13.3 million in Q3 2023, due to the completion of certain clinical trials and lower headcount related costs.
• Selling, general, and administrative expenses increased to $26.5 million in Q3 2024 from $22.7 million in Q3 2023, primarily due to higher headcount and marketing costs related to the Vafseo launch.
• The company is preparing for the U.S. launch of Vafseo, expected in January 2025, and has secured Transitional Drug Add-on Payment Adjustment (TDAPA) reimbursement starting January 1, 2025.
• Auryxia is set to lose exclusivity in the U.S. in March 2025, which is expected to impact future revenue.
• The company believes its cash resources and expected revenue will be sufficient to fund its operating plan for at least twelve months from the filing of this report.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the increased net loss, decreased product revenue, and the upcoming loss of exclusivity for Auryxia. However, the launch of Vafseo and the securing of TDAPA reimbursement provide some positive outlook.

Positives

• Vafseo received FDA approval and is expected to launch in the U.S. in January 2025.
• Vafseo will be eligible for TDAPA reimbursement starting January 1, 2025.
• The company believes its cash resources and expected revenue will be sufficient to fund its operating plan for at least twelve months from the filing of this report.
• Research and development expenses decreased due to the completion of certain clinical trials.

Negatives

• Product revenue decreased by 11% year-over-year due to lower sales volume of Auryxia.
• Auryxia is set to lose exclusivity in the U.S. in March 2025, which is expected to impact future revenue.
• The company reported a net loss of $20 million for Q3 2024, an increase from the $14.5 million loss in Q3 2023.
• Selling, general, and administrative expenses increased due to Vafseo launch preparations.

Risks

• The company's ability to generate revenue from Auryxia will be impacted by the loss of exclusivity in March 2025.
• The company's ability to successfully commercialize Vafseo will depend on contracting with dialysis organizations.
• The company may require substantial additional financing to fund its business.
• The company's stock price has been and may continue to be volatile.
• The company is subject to complex regulatory schemes and may face penalties for non-compliance.
• The company relies on third parties for manufacturing and distribution, which could lead to supply chain disruptions.
• The company may face competition from other companies developing similar products.
• The company may not be able to protect its intellectual property rights.
• The company may be subject to product liability claims.
• The company may not be able to attract, retain and motivate senior management and qualified personnel.

Future Outlook

The company expects to launch Vafseo in the U.S. in January 2025 and believes its cash resources and expected revenue will be sufficient to fund its operating plan for at least twelve months from the filing of this report. The company also expects Auryxia to lose exclusivity in the U.S. in March 2025.

Management Comments

• The company believes focusing on all patients who can realize a meaningful benefit from our medicines, will result in delivering value for our stockholders.
• The company plans to work with payors and providers to seek to continue the use of Auryxia beyond LoE.

Industry Context

The report highlights the challenges and opportunities in the biopharmaceutical industry, particularly in the renal space, with a focus on the commercialization of new therapies and the impact of generic competition. The company is navigating the launch of Vafseo while preparing for the loss of exclusivity for Auryxia, a common challenge for pharmaceutical companies.

Comparison to Industry Standards

• The decrease in product revenue for Auryxia is consistent with the expected impact of generic competition and the inclusion of phosphate binders in the ESRD bundle, which is a common trend in the pharmaceutical industry.
• The increase in selling, general, and administrative expenses is typical for a company preparing for a product launch, such as Vafseo.
• The decrease in research and development expenses is likely due to the completion of certain clinical trials, which is a normal part of the drug development lifecycle.
• The company's reliance on third-party manufacturers and distributors is a common practice in the pharmaceutical industry, but it also exposes the company to supply chain risks.
• The company's efforts to secure reimbursement for Vafseo are consistent with industry practices, but the outcome is uncertain.

Stakeholder Impact

• Shareholders may experience dilution if the company raises additional capital through equity offerings.
• Employees may be affected by potential future workforce reductions or restructuring activities.
• Customers (dialysis organizations and patients) will be impacted by the launch of Vafseo and the loss of exclusivity for Auryxia.
• Suppliers and manufacturers may be affected by changes in the company's supply chain and manufacturing agreements.
• Creditors may be affected by the company's ability to repay its debt obligations.

Next Steps

• The company will focus on the U.S. launch of Vafseo in January 2025.
• The company will continue to work with payors and providers to seek to continue the use of Auryxia beyond LoE.
• The company will continue to explore additional development opportunities to expand its pipeline and portfolio of novel therapeutics.

Key Dates

Keywords

Vafseo, Auryxia, anemia, chronic kidney disease, CKD, dialysis, TDAPA, commercialization, FDA, revenue, net loss, intellectual property, clinical trials, regulatory approval, manufacturing, supply chain, competition